InterMune to Release Second Quarter Financial Results on July 27
BRISBANE, Calif., July 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will release second quarter 2010 financial results on Tuesday, July 27, 2010 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.
To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 85459924. To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 85459924.
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone, for which InterMune has completed the Phase 3 CAPACITY program in patients with IPF. A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA). The hepatology portfolio includes the HCV protease inhibitor compound danoprevir (also known as RG7227 and ITMN-191) that entered Phase 2b in August 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.
SOURCE InterMune, Inc.
Posts
Should get an update on Danoprevir (also known to us as ITMN-191 & RG7227). Now that this drug is tied to Ritonavir as a boosting agent (http://www.hivandhepatitis.com/2010_conference/easl/docs/0420_2010_b.html)it's unclear whether this will be a boon or a burden for the drug. At it's most effective dose (Danoprevir/ritonavir 200/100 mg BID) we still have a BID drug tied to a boosting agent that is known for kidney toxicity (could be a problem in patients with advanced HCV disease)and a multitude of other drug interactions. The other side of this coin is that we'll probably see very high Cmin/IC50 ratios which could be a significant advantage in preventing viral resistance and/or overcoming existing resistance.
ReplyDelete